In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective alternative to painful daily treatment for a rare disorder, according to research published Jan. 29 in ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. After a thorough review ...

At the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long term low risk stocks. As the DeepSeek craze ignites a sell-off in the tech ...

Eli Lilly and Company (NYSE:LLY) generated $11.4 billion in revenue, reflecting a 20.5% year-over-year increase. The growth was primarily fueled by strong performances from Mounjaro and Zepbound ...

Eli Lilly and Company (NYSE:LLY) generated $11.4 billion in revenue, reflecting a 20.5% year-over-year increase. The growth was primarily fueled by strong performances from Mounjaro and Zepbound ...